KEGG   DRUG: Nadofaragene firadenovec
Entry
D12531                      Drug                                   
Name
Nadofaragene firadenovec (USAN/INN);
Nadofaragene firadenovec-vncg;
Adstiladrin (TN)
Product
ADSTILADRIN (Ferring Pharmaceuticals)
Remark
ATC code: L01XL10
Product: D12531<US>
Efficacy
Antineoplastic
  Disease
Bladder cancer [DS:H00022]
  Type
Gene therapy product
Comment
Recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2bTreatment of non-muscle-invasive bladder cancer resistant to Bacille Calmette-Guerin (BCG)
Target
IFNA2 [HSA:3440] [KO:K05414]
  Pathway
hsa05200  Pathways in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL10 Nadofaragene firadenovec
      D12531  Nadofaragene firadenovec (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interferons
    IFNA2
     D12531  Nadofaragene firadenovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12531
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12531
Other DBs
CAS: 1823059-12-6
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system